Johnson & Johnson (JNJ) is Gaining from Its Strong Innovative Medicine Growth

Johnson & Johnson (JNJ) is Gaining from Its Strong Innovative Medicine Growth Soumya Eswaran Mon, April 13, 2026 at 9:46 AM EDT 3 min read JNJ MSTR CL=F ^GSPC Mar Vista Investment Partners, LLC , an investment management company, released its “Mar Vista U.S. Quality Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here . U.S. equities entered 2026 with sustained momentum, despite market leadership evolving significantly over the first quarter. Initial support in equities was hampered by tariff uncertainty, doubts about AI-driven growth sustainability, and emerging private credit concerns, before geopolitical challenges. The quarter saw the lowest performance for U.S. equities in this volatile environment, influenced by rising oil prices due to the Middle East conflict, altering inflation and interest rate expectations. The Mar Vista U.S. Quality strategy returned -7.24% net-of-fees in the quarter vs Russell 1000® Index’s -4.18% and the S&P 500® Index’s -4.33% returns. The firm believes the market is transitioning towards high-quality businesses with strong competitive advantages. Please review the Strategy’s top five holdings to gain insights into their key selections for 2026. In its first-quarter 2026 investor letter, Mar Vista U.S. Quality Strategy highlighted Johnson & Johnson (NYSE: JNJ ). Johnson & Johnson (NYSE:JNJ) is a leading global healthcare company that engages in the research and development, manufacture, and s…